[1] |
WANG Haodi, DENG Zhengming, WANG Gang, JIANG Zhiwei.
Disease burden in colorectal cancer attributed to fasting hyperglycemia in china from 1990 to 2021 and projections of future trends
[J]. Chinese Journal of Oncology Prevention and Treatment, 2025, 17(1): 61-67.
|
[2] |
CAO Le, MA Minmin, LI Wenmin, SHUI Mingming, JIANG Cheng.
Trend of mortality and disease burden of gastric cancer in China,2004—2021
[J]. Chinese Journal of Oncology Prevention and Treatment, 2025, 17(1): 68-73.
|
[3] |
XUAN Wenzhen, GONG Jianmin, LI Na.
Incidence,mortality,and disease burden of cervical cancer in China,1990—2021: trends over the past 30 years and future prediction
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(6): 694-700.
|
[4] |
PAN Hongxin, CUI Wangfei, LYU Licheng, WANG Xinzheng, CAO Ling, ZHANG Yongzhen.
Analysis of the incidence and mortality of malignant tumors in tumor registration areas of Shanxi Province,2020
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(6): 700-706.
|
[5] |
JIANG Yuan, WANG Xiaoyan, LEI lei, LIU Lihua, WU Danfeng, ZHANG Siqi, TANG Dairong, FAN Lingli, FENG Gang, XUE Xiaojing.
Summary of the best evidence for blood glucose management in cancer patients with immune checkpoint inhibitors inducing hyperglycemia
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(6): 722-728.
|
[6] |
HUANG Shihuan, LAN Huiyu, NONG Xiaolian, LI Fanrong, ZHAO Fengjuan, YOU Xuemei.
Network analysis of concurrent symptoms and core symptom identification in patients with intermediate and advanced hepatocellular carcinoma after surgery
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(6): 729-735.
|
[7] |
LIU Jingqian, ZHANG Yajing.
Strategies for prevention,control and management of CAR-T cell therapy related adverse reactions
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 540-548.
|
[8] |
WANG Huijuan, CHEN Wenming, GENG Chuanying, YANG Guangzhong .
Clinical characteristics of patients with relapsed/refractory multiple myeloma after CAR-T cell therapy
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 549-553.
|
[9] |
DONG Junling, YANG Hui, LI Na.
Trend of the incidence of gastric cancer in China,1992—2021
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 593-597.
|
[10] |
ZHAO Min, LI Rongrong, LI Boyan, WANG Wenchang, DU Shengyan, YANG Junhan, LI Huaihao, BAO Yinghui, SHI Yueting, HE Yao, LIU Miao.
Hotspots and trends of research on early esophageal cancer treatment:visual analysis based on CiteSpace
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 606-605.
|
[11] |
ZHANG Xiaomeng, WANG Yue, WAN Qiaoqin.
Summary of evidence for the management of drug-related symptoms during endocrine therapy in breast cancer patients
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 615-621.
|
[12] |
SU Lili, LAN Zhenyu, LIN Huizhe, YAN Fangna, CHEN Weilian, LIN Wei.
Effects of sarcopenia on prognosis of prostate cancer treatment: a Meta-analysis
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(4): 487-493.
|
[13] |
YAN Haiqing, LAI Qinqiao, WU Liucheng, WANG Ting'an, XIA Xiang, HUANG Mingwei, QIN Yuzhou.
Effects of SH3BGRL on proliferation and migration of gastric cancer cells
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(3): 285-294.
|
[14] |
XIE Changquan, HE Fengyi, LU Guodong, LI Qiuyun.
Andrographolide combined with doxorubicin induces cell death in breast cancer cell via ROS-dependent DNA damage
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(3): 302-307.
|
[15] |
SUN Xiaoxia, WANG Yuping, SI Meili, ZHU Jing, ZHONG Mei.
Trends of incidence and mortality and the age-period-cohort of cervical cancer in China,1990—2019
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(3): 317-320.
|